Showing results (31-40 of 36) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Pharmaceutical Sciences|December 1, 1990
Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation-enhancing vehiclesB J Aungst, J A Blake, N J Rogers, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1990
Inhibition of leucine enkephalin metabolism in rat blood, plasma and tissues in vitro by an aminoboronic acid derivativeM A Hussain, S M Rowe, A B Shenvi, et al.Journal of Pharmaceutical Sciences|January 1, 1995
Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying N-terminal amino acidsM A Hussain, R Seetharam, R R Wilk, et al.Pharmaceutical Research|May 1, 1995
Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonistB J Aungst, J A Blake, N J Rogers, et al.Bioorganic & Medicinal Chemistry Letters|March 4, 2000
The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligandR A Galemmo, B L Wells, K A Rossi, et al.Journal of Medicinal Chemistry|February 15, 2001
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor XaD J Pinto, M J Orwat, S Wang, et al.Pageof 4